Trials / Completed
CompletedNCT01511913
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,411 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to examine the safety of Ipilimumab and patterns of use in the treatment of unresectable or metastatic melanoma in the post-approval setting
Detailed description
Time Perspective: this study does have a retrospective component involving a subset of patients
Conditions
Timeline
- Start date
- 2012-06-03
- Primary completion
- 2018-03-30
- Completion
- 2019-12-12
- First posted
- 2012-01-19
- Last updated
- 2021-12-28
Locations
186 sites across 15 countries: United States, Argentina, Australia, Austria, Belgium, Canada, France, Germany, Greece, Ireland, Israel, Poland, Spain, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT01511913. Inclusion in this directory is not an endorsement.